Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real‐life observation

Bagnasco, Diego; Menzella, Francesco; Caminati, Marco; Guida, Giuseppe; Bonavia, Marco; Riccio, Annamaria; Milanese, Manlio; Manfredi, Andrea; Senna, Gianenrico; Passalacqua, Giovanni

doi:10.1111/all.13937

Cited by 39 publications

(46 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the opposite, the impact of MEP on atopic dermatitis was clinically more apparent, despite in our population, the affected patients were only 9 (7%). Finally, it is noteworthy that the 27 patients who previously failed to respond to Omalizumab, had all a significant benefit with MEP, as already described [34]. The occurrence of adverse events was low.…”

Section: Discussionsupporting

confidence: 60%

One year of mepolizumab. Efficacy and safety in real-life in Italy

Bagnasco

Caminati

Menzella

et al. 2019

Pulmonary Pharmacology & Therapeutics

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 60%

One year of mepolizumab. Efficacy and safety in real-life in Italy

Bagnasco

Caminati

Menzella

et al. 2019

Pulmonary Pharmacology & Therapeutics

Self Cite

View full text Add to dashboard Cite

“…In the OSMO study, a multicenter, open-label, single-arm, 32-week trial, patients with severe asthma uncontrolled by omalizumab showed an improvement in asthma control after switching to mepolizumab [75]. Interestingly, this result was confirmed by real-world evidence [76]. Preliminary findings also suggest that that in patients treated with mepolizumab who had poor asthma symptom control, switching to benralizumab led to improved QoL scores and reduced OCS maintenance doses [77].…”

Section: Discussionmentioning

confidence: 88%

Severe Asthma and Biological Therapy: When, Which, and for Whom

et al. 2019

View full text Add to dashboard Cite

Asthma is a heterogeneous chronic inflammatory disease of the airways that affects approximately 300 million people worldwide. About 5-10% of all asthmatics suffer from severe or uncontrolled asthma, associated with increased mortality and hospitalization, reduced quality of life, and increased health care costs. In recent years, new treatments have become available, and different asthma phenotypes characterized by specific biomarkers have been identified. Biological drugs are currently indicated for patients with severe asthma that is not controlled with recommended treatments. They are mostly directed against inflammatory molecules of the type 2 inflammatory pathway and are effective at reducing exacerbations, maintaining control over asthma symptoms, and reducing systemic steroid use, which is associated with well-known adverse events. Although biological drugs for severe asthma have had a major impact on the management of the disease, there is still a need for head-to-head comparison studies of biologics and to identify new biomarkers for asthma diagnosis, prognosis, and response to treatment. Identifying novel biomarkers could facilitate the development of therapeutic strategies that are precisely tailored to each patient's requirements.

show abstract

“…In the OSMO study, among 145 patients who were switched to mepolizumab, the rate of clinically significant exacerbations during the 32-week study period decreased by 64% compared with the year prior to study enrollment 6 . After 1 year of mepolizumab treatment, Bagnasco et al 7 registered a decrease in the mean exacerbation rate of 81% in their 27 patients. Similarly to what was found by Bagnasco et al, 7 in our 41 patients the reduction in the mean exacerbation rate was 83%.…”

Section: Discussionmentioning

confidence: 93%

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy

Carpagnano

Pelaia

D’Amato

et al. 2020

Ther Adv Respir Dis

View full text Add to dashboard Cite

Background: Current availability of several biologic treatments for severe asthma makes it possible to choose the most appropriate for each patient. Sometimes a good percentage of patients with severe asthma may be eligible for biologics that target either the allergic phenotype or the eosinophilic one, but not all respond to that selected as first choice. The aim of our real-life study was to assess whether, for patients with severe eosinophilic allergic asthma, not previously controlled by the anti-IgE omalizumab, the shift to another biologic targeting interleukin-5, such as mepolizumab, may represent a good therapeutic choice. Methods: A total of 41 consecutive patients with severe, persistent allergic, eosinophilic asthma, uncontrolled despite treatment with omalizumab, were enrolled in seven certified Clinical Respiratory Units of Southern Italy (Catania, Catanzaro, Foggia, Bari, Palermo, and two University Respiratory Units of Naples) and shifted to mepolizumab without a wash-out period. Data at baseline, after at least 12 months of therapy with omalizumab, and after at least 12 months of treatment with mepolizumab were collected. Results: After at least 12 months of therapy with mepolizumab, patients experienced a significant decrease in the number of exacerbations/year (5.8 ± 1.8 versus 0.7 ± 0.9, p < 0.0001), an increment of asthma control test score (12 ± 2.7 versus 21.9 ± 2.7, p < 0.0001), an increase in pre-bronchodilator forced expiratory volume in 1 s (1.56 ± 0.45 l versus 1.86 ± 0.52 l, p < 0.0001), and a reduction of blood eosinophils (584 ± 196 cells/µl versus 82 ± 56 cells/µl, p < 0.0001). The percentage of patients who were dependent on corticosteroids significantly decreased from 46% at baseline to 5% during treatment with mepolizumab. Conclusion: Results of our real-life multicentric experience confirms that the shift to mepolizumab could be a good therapeutic strategy in severe eosinophilic allergic asthma not previously controlled by omalizumab. The reviews of this paper are available via the supplemental material section.

show abstract

Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real‐life observation

Cited by 39 publications

References 8 publications

One year of mepolizumab. Efficacy and safety in real-life in Italy

One year of mepolizumab. Efficacy and safety in real-life in Italy

Severe Asthma and Biological Therapy: When, Which, and for Whom

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy

Contact Info

Product

Resources

About